A prospective randomized trial of fk506 versus cyclosporine after human pulmonary transplantation by Griffith, BP et al.
i 
! , 
------------ --------------
848 TRANSPLANTATION Vol. 57. No. Ii 
lograft physiology. Transplant Proc 1992; 24: 1105. 
24. Lillehei RC. Idezuki Y, Feemster JA. et al. Transplantation of 
stomach, intestine and pancreas: experimental and clinical ob-
servations. Surgery 1967: 62: 721. 
25. Starzl TE, Rowe M, Todo S. et al. Transplantation of multiple 
abdominal viscera. JAMA 1989: 26: 1449. 
26. Schraut WH. Abraham VS, Loe KKW. Portal versus caval ve-
nous drainage of small bowel allografts: technical and meta-
bolic consequences. Surgery 1986; 99: 193. 
27. Koltun WA, Madara JL, Smith RJ. Kirkman RL. Metabolic as-
pects of small bowel transplantation in inbred rats. J Surg Res 
1987; 42: 341. 
28. Murase N, Demetris AJ, Furuya T, et al. Comparison of the 
small intestine after multivisceral transplantation and the 
small intestine transplanted with portal versus caval drain-
age. Transplant Proc 1992; 24: 1143. 
0041-1337/94/5706-848$03.00/0 
TRANSPLANTATION 
Copyright (i:) 1994 by Williams & Wilkins 
29. Shaffer D, Diflo T, Love W, Clowes GHA, Maki T, Monaco AP 
Immunologic and metabolic effects of caval versus portal v~ 
nous drainage in small-bowel transplantation. Surgery 1988' 
104: 518. . 
30. Hutter JA. Scott JA, Wreghitt T, et aI. The importance of cvto-
megalovirus in heart-lung transplant recipients. Chest 1989: 
95: 627. 
3l. Nicol D, McDonald AS. Belitsky P. et al. Reduction by combina. 
tion prophylactic therapy with CMV hyperimmune globulin 
and acyclovir of the risk of primary CMV disease in renal 
transplant recipients. Transplantation 1993; 55: 841. 
32. Caine RY, Sells RA. Pena JR, et al. Induction of immunological 
tolerance by porcine liver allografts. Nature 1969; 223: 472. 
Received 26 May 1993. 
Accepted 14 September 1993. 
Vol. 57. 84S-851. No.6. March 1994 
Printed in U. S.A 
A PROSPECTIVE RANDOMIZED TRIAL OF FK506 VERSUS 
CYCLOSPORINE AFTER HUMAN PULMONARY 
TRANSPLANTATION1 
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We have conducted a unique prospective random-
ized study to compare the effect of FK506 and cyclos-
porine (CsA) as the principal immunosuppressive 
agents after pulmonary transplantation. Between 
October 1991 and March 1993. 74 lung transplants (35 
single lung transplants [SLT1, 39 bilateral lung trans-
plant [BLTl) were performed on 74 recipients who 
were randomly assigned to receive either FK or CsA. 
Thirty-eight recipients (19 SLT, 19 BLT) received FK 
and 36 recipients (16 SLT, 20 BLT) received CsA. Re-
cipients receiving FK or CsA were similar in age, gen-
der, preoperative New York Heart Association func· 
tional class. and underlying disease. Acute rejection 
(ACR) was assessed by clinical, radiographic, and his-
tologic criteria. ACR was treated with methylpred-
nisolone, 1 g i.vJday, for three days or rabbit antithy-
mocyte globulin if steroid-resistant. 
During the first 30 days after transplant. one pa-
tient in the FK group died of cerebral edema. while 
two recipients treated with CsA died of bacterial 
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pneumonia (J) and cardiac arrest (1) (P=NS). AJ-
though one-year survival was similar between the 
groups, the number of recipients free from ACR in the 
FK group was significantly higher as compared with 
the CsA group (P<0.05)' Bacterial and viral pneumo-
nias were the major causes of late graft failure in 
both groups. The mean number of episodes of ACRJ 
100 patient days was significantly fewer in the FK 
group (1.2) as compared with the CsA group (2.01 
(P<O.OS). While only one recipient (1136=3%) in the 
group treated with CsA remained free from ACR 
within 120 days of transplantation. 13% (5/38) of the 
group treated with FK remained free from ACR dur-
ing this interval (P<0.05). The prevalence of bacterial 
infection in the CsA group was 1.5 episodes/IOO pa-
tient days and 0.6 episodes/lOO patient days in the FK 
/,rroup. The prevalence of cytomegaloviral and fungal 
infection was similar in both groups. 
Although the presence of bacterial, fungal, and viral 
infections was similar in the two groups, ACR oc-
curred less frequently in the FK-treated group as com· 
pared with the CsA-treated group in the early postop-
erative period «90 daysl. Early graft survival at 30 
days was similar in the two groups, but intermediate 
graft survival at 6 months was better in the FK group 
as compared with the CsA group. 
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TABLE 1. Characteristics ofrecipients in a randomized trial 
of FK506 vs. CsA 
Age 
Mean:!: SD 
Range 
Gender (male/female) 
Underlying disease 
Septic obstructive LD 
Nonseptic obstructive LD 
Restrictive LD 
Pulmonary hypertension 
Other 
Type of transplant procedure 
Single lung Tx 
Bilateral lung Tx 
FK506 esA 
39 ~ 18 
10-66 
15/23 
12 
17 
3 
5 
1 
19 
19 
41 ~ 10 
O1~S 
15/21 
10 
10 
4 
12 
o 
16 
20 
Significant mortality still occurs due to infection and acute 
and chronic rejection in adult lung allograft recipients who 
have received esA-based immunosuppression ( 1 ). In the first 
year after transplant, infection is the most significant cause 
of death (55%) followed by primary graft failure (30%), and 
rejection (15%) (2). Later, obliterative bronchiolitis (OB)* is a 
major disability and morbidity, (27%) and combined with in-
fection (40%) it is the most troublesome problem. Further-
more. the toxicities of esA-based therapy-including sys-
temic hypertension, hypercholesterolemia, and diminished 
renal function-limit its dosage. 
FK506 had demonstrated a dramatic immunotherapeutic 
advantage in our pediatric cardiac recipients (3). Accordingly 
in 1990 FK506 was introduced as the primary immunosup-
pressive therapy in our pediatric lung recipients with the 
hope that this would result in steroid sparing and reduced 
toxicity (4), Because we were also encouraged by the prelimi-
nary results in lung recipients, a prospective randomized 
clinical trial was initiated in adults designed to compare FK 
and esA. The aim of this study was to determine the relative 
efficacy of FK. low-dose steroid (prednisone 0.10-0.15 mg/kg), 
and AZA as standard immunosuppression for lung allograft 
recipients. This communication reports the impact of FK on 
episodes of rejection and infection during the first year after 
isolated lung transplantation. 
~1AqbolAip AND METHODS 
Patient popuLation. Between October 1991 and March 1993. 74 
isolated lung transplants were performed on 74 patients. Patients 
were randomly aSSigned by alternate treatments to receive either FK 
or esA combined with low-dose sterOids and AZA as outlined below. 
Thirty-eight reCipients 119 single lung transplants I SLT1. 19 bilateral 
lung transplants I BLTll received FK. and thirty-six reCipients (16 
SLT. 20 BLT) received CsA. Recipients receiving FK or CsA were 
Similar In age, gender. preoperative New York Heart Association 
functlonal class. and underlying disease tTable 11. 
I mmunosupprcsswe Protocols. FK group: Immediately before 
transplantation. all patients were given an mtravenous loading dose 
14 mg;kg) ofAZA. and 500 mg of methylprednisolone was mfused Just 
pnor to revascularizatlon of the allolO'aft. AZA was dosed 15-2.5 mg, 
accordmg to WBC tolerance 15000 mme,. and postoperatively the 
steroids were continued every 13 hr for three 125 mg doses. fK was 
gwen by contmuous mfusion as soon as the recipient was cardiovas-
cularlv stable 1 usuallv 6--8 hr after admission to the mtensive care 
UnIt). at a dose 01 0.025 mg/kg/day. The FK dose was then increased 
• AbbreVlatlOns: ACR. acute rejection: BLT. bilateral lung trans-
plant: UB. obliterative bronchiolitis: SLT. single lun!!, transplant: 
TBBx. trans bronchial biopsy. 
toward. 0.075 mglkglday to reach a target serum level of 1K~1KR 
nglml. While most achieved this within three days, at times nephro-
toxicity necessitated a low-target or more gradual increased dosage_ 
Once recipients were able to take oral medications, FK was pre-
scribed at a dose of 0.15 mglkglday in two divided doses and adjusted 
accordingly to target levels. FK was measured by enzyme-linked 
immunosorbent assay technique of Tamaura (5). Additional steroids 
were not given unless two episodes of acute rejection occurred during 
the first six weeks. If required, maintenance prednisone was begun 
at 0.11H>.2 mglkg/day. 
CsA group: Patients randomized to CsA received methylpred-
nisolone and prednisone and similar perioperative doses of AZA and 
intravenous CsA(2.5 mglkg/day) were also begun when the recipient 
was stable postoperatively. When gastrointestinal function resumed, 
oral CsA was begun at a dose of 2.5 mglkglday given twice daily. As 
with the FK protocol, the dose of CsA was adjusted to an ideal target 
level of TR~1MMM nglml, but nephrotoxicity was respected. 
Rejection therapy: Acute rejection was treated with methylpred-
nisolone. 1 g i. v. daily, for three successive days for the first and 
second episodes of acute rejection. Persistant rejection and oblitera-
tive bronchiolitis were treated with rabbit antithymocyte globulin 
prepared in our laboratory and delivered intramuscularly (1.5 mgl 
kg/day) for five days. 
Measure of effectiveness: Rejection of the allograft was assessed 
by radiograph, spirometry, and biopsy \2,6). Histologic confirmation 
of at least grade 2 of rejection by trans bronchial biopsy (TBBx) was 
required except for the few with early diffuse radiographic infiltrates 
that responded promptly to the first dose of methylprednisolone. 
Surveillance TBBx was performed at two-week intervals during the 
first 2-3 months and thereafter the interval was increased based on 
the recipient's clinical history. 
Statistical analysis. Actuarial survival and freedom from acute 
rejection were computed by the method of life table analysis (7). 
Linearized rates (events per 100 patient-days) were compared with 
the maximum likelihood ratio test (8). Comparisons among the FK 
and CsA groups were made by the Mann-Whitney rank sum test (9). 
A computer program package IStatsoft. CSS Statistica. Thlsa OK) 
was used for statistical analysis. 
RESULTS 
Mortality. One- and 6-month survivals were similar in the 
b'TOUPS (Fig. 1): 80% of the FK group and 71 % of the CsA 
group had the cumulative probabilities of being alive one 
year after transplantation. 
One operative death occurred in the FK group, and two 
deaths occurred in the CsA group (Table 1>' The majority of 
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FIGURE 1. SUrvlval after pulmonary transplantatlon-a random-
ized trial of FK vs. CsA. 
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FIGURE 2. Frequency of acute rejection after pulmonary 
transplantation-a randomized trial ofFK vs. CsA(P<O.05 by Mann-
Whitney analysis). 
late deaths were related to allograft infection in both groups. 
In the CsA group, ACR contributed to fatal graft failure in 
both instances. whereas the death in the FK group was not 
related to ACR. 
Rejection. A total of 45 episodes of rejection were diagnosed 
among the recipients who received FK Forty-two episodes of 
rejection were confirmed histologically, while three episodes 
were diagnosed by radiograph. Seventy-eight episodes of re-
jection (76 episodes by TBBx. two by clinical findings) were 
diagnosed in the CsA group. The mean frequency of rejection 
per 100 patient days in the FK group (1.2) was significantly 
lower as compared with the CsA group (2.0) (P<0.05 by 
Mann-Whitney) (Fig. 2). The average times to rejection were 
26 and 22 days. respectively. in the FK and CsA patients. and 
the CsA recipients required additional3-day courses of meth-
ylprednisolone as compared with FK recipients. although 
this difference barely reached statistically significant levels 
(P=O.05) (Fig. 3). Moreover. 13/38 (34%) of the FK recIpients 
were steroid-free; whereas. only 2136 (6%) of the CsA recipi-
ents were steroid-free (P<O.OOOI by chi-square analysis). At 
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FIGURE 3. Requirement of methylprednisolone for episodes of acute 
reJection-a randoauzed trial of FK vs. CsA (P=O.05 by Mann-Whit-
neyanalysisl. 
90 days the average dose of prednisone was 11±4 mg/day in 
the CsA group and 9±4 mg/day in the FK patients (NS). 
All of the recipients in the CsA group experienced at least 
one episode of rejection within 6 months posttransplant, and 
11 % (4138) of FK recipients were free from rejection (Fig. 4). 
Two recipients in the FK group and four recipients in the CsA 
group developed OB during this observation period between 
October 1991 and April 1993. All of the recipients with OB 
were diagnosed by surveillance TBBx and currently are in 
remission following adjunctive immunosuppressive therapy 
with methylprednisolone and/or rabbit antithymocyte globu-
lin. 
CsA to FK switch. Thirteen nonrandomized recipients ini-
tially treated with CsA were switched to FK because of un-
controllable multiple episodes of ACR. Acute rejection re-
solved in eight patients, improved in two, was unaffected in 
two, and persisted in one. 
Infection. Although prevalence ofinfection in the FK group 
(0.6 episodeS/100 patient days) was less as compared with 
that of the CsAgroup (1.5 episodes/lOO patient days), this did 
not reach statistical significance (Fig. 5). Bacterial and viral 
pneumonia were the primary causes of death after 30 days 
posttransplant (Table 2). Although donor and recipient 
serostatus was similar between the groups, only one recipi-
ent in the FK group experienced symtomatic CMV compared 
with five recipients in the CsAgroup during the first 120 days 
after transplant. The prevalence of fungal infection in the FK 
(7 episodes) and CsA (5 episodes) groups was similar. 
Metabolic studies and side effects. Although transient renal 
dysfunction immediately after transplantation was fre-
quently observed with intravenous administration of FK or 
CsA, the majority of cases were well controlled with con-
comitant administration of low-dose prostaglandin E\ (0.01 
p.glk.g/hr). Notably absent in the FK group were complaints 
of gingival hyperplasia or hirsutism, which have frequently 
been seen in CsA recipients. Systolic and diastolic arterial 
pressures were similar in the two groups during this obser-
vation period. Twelve recipients in the FK group (12138) and 
15 recipients in the CsA group (15/36) required antihyper-
tensive therapy, consisting of enalapril maleate or diltiazem 
hydrochloride. 
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FIGURE 4. Freedom from acute rejection after pulmonarY 
transplantation-randomIzed trial of FK YS. CsA (P<O.05 by gener-
alized Wilcoxon test). 
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FIGURE 5. Frequency of infection after pulmonary transplantat-
ion-a randomized trial of FK vs. CsA. 
TABLE 2. Causes of early and late morbidity following lung TX 
in a randomized trial of FK506 vs. CsA 
Group 
Early 
FK506 
CsA 
Late 
FK506 
CsA 
Mortality \s30 days) 
3% (1/38) 
6% (2136) 
13% (5/38) 
16% (6/36) 
Cause of desth (n) 
Toxoplasmosis (I) 
Bacterial pneumonia \ 1) 
Cardiac arrest (1) 
P aeruginosa pneumonia (2) 
Adenoviral pneumonia (2) 
CMV pneumonia (I) 
P aeruginosa pneumonia (3) 
Adenoviral pneumonia (1) 
PTLD (l) 
Respiratory failure 
(reason unknown) (1) 
DISCUSSION 
This randomized trial of FK versus CsA after isolated pul-
monary transplantation suggests that FK based-immuno-
suppression resulted in less-frequent moderate and severe 
acute rejection. In addition, 11% of FK recipients were free 
from rejection 6 months posttransplant, whereas all of the 
esA recipients experienced at least one episode of rejection 
during the same period. This is noteworthy primarily be-
cause lung transplant recipients experience a much higher 
incidence of acute rejection as compared with the cardiac 
transplant recipients 110) and more frequent and more se-
vere acute rejection were most significant risk factors for the 
subsequent development of OB. the leading cause of late 
morbidity and mortality. The potential impact of FK on OB 
has yet to be determined. However. the lower prevalence of 
acute rejection in the FK group is encouraging \ 11 l. 
Infection remains the most significant cause of early and 
intermediate mortality in this randomized study, and no sig-
nificant differences were observed between the two groups in 
the prevalence of infection and death from infection. Thus 
better immunosuppressive protocols and aggressive antimi-
croorganic therapy for adequate control of infection are still 
warranted for further improvement of the quality of life and 
survival after pulmonary transplantation. 
Although transient renal dysfunction was observed in the 
significant number of patients in both the FK and esA 
groups, neurological complications and gingival hyperplasia 
or hirsutism were not encountered in the FK group. 
In summary, the current randomized trial of FK versus 
CsA demonstrated fewer episodes of rejection in the FK 
group, although the prevalence of infection and survival were 
similar in the groups. The impact of FK on long-term fol-
low-up is unclear and needs to be determined. 
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